BeStock  

Zoetis ZTS

US equityMarket cap rank #616Drug Manufacturers - Specialty & Generic
$79.11 −$1.68 (-2.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $78.16 -1.20%
Open$81.73
Prev close$80.79
Day range$78.80 – $83.08
Volume6.10M
Market cap$32.14B
P/E (TTM)13.3
Dividend yield2.64%

Earnings

Average move on report day±6.4%last 16 reports
Closed higher7 of 1644% of the time
Best reaction+6.3%
Worst reaction-21.5%

Stock move on the day after each report

-6.7%2023/Q4+5.5%2024/Q1+6.0%2024/Q2-3.7%2024/Q3-5.1%2024/Q4-5.2%2025/Q1-3.7%2025/Q2-13.8%2025/Q3-2.4%2025/Q4-21.5%2026/Q1+3.9%2026/Q2-7.9%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q35 Nov 2026Pre Market±8.2%-7.95%Within range
2026/Q26 Aug 2026Pre Market±9.5%+3.87%Within range
2026/Q17 May 2026Pre Market±7.3%-21.50%Bigger than priced
2025/Q412 Feb 2026Pre Market±6.4%-2.35%Within range
2025/Q34 Nov 2025Pre Market±6.0%-13.78%Bigger than priced
2025/Q25 Aug 2025Pre Market±7.5%-3.75%Within range
2025/Q16 May 2025Pre Market±7.3%-5.18%Within range
2024/Q413 Feb 2025Pre Market±6.4%-5.15%Within range
2024/Q34 Nov 2024Pre Market±7.7%-3.72%Within range
2024/Q26 Aug 2024Pre Market±9.5%+5.99%Within range
2024/Q12 May 2024Pre Market±6.9%+5.51%Within range
2023/Q413 Feb 2024Pre Market±6.2%-6.71%Bigger than priced
2023/Q32 Nov 2023Pre Market±6.2%+6.25%Bigger than priced
2023/Q28 Aug 2023Pre Market±6.7%+4.77%Within range
2023/Q14 May 2023Pre Market±6.0%+0.42%Within range
2022/Q414 Feb 2023Pre Market±4.6%+5.37%Bigger than priced

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Parasiticides$576.00M 24.1%
  • Vaccines$540.00M 22.6%
  • Dermatology$398.00M 16.6%
  • Anti-infectives$282.00M 11.8%
  • Pain and sedation$200.00M 8.4%
  • Other pharmaceuticals$170.00M 7.1%
  • Animal health diagnostics$128.00M 5.4%
  • Medicated feed additives$68.00M 2.8%
  • Contract manufacturing & human health$29.00M 1.2%

Latest reported quarter: Q3, ended Sep 2026

Revenue$2.39B-1.3% YoY
Operating profit$906.00M-3.2% YoY
Net profit$591.00M-18.0% YoY
Diluted EPS$1.44-11.7% YoY
Free cash flow$717.00M-10.2% YoY
Operating cash flow$824.00M

Revenue, last 8 quarters

$2.3BDec '24$2.2BMar '25$2.5BJun '25$2.4BSep '25$2.4BDec '25$2.3BMar '26$2.5BJun '26$2.4BSep '26

Net profit, last 8 quarters

$581.0MDec '24$602.0MMar '25$726.0MJun '25$721.0MSep '25$624.0MDec '25$601.0MMar '26$691.0MJun '26$591.0MSep '26

Profitability & balance sheet

Gross margin71.6%
Operating margin37.7%
Net margin26.4%
Return on equity57.6%
Return on assets16.6%
Return on invested capital20.3%
Current ratio2.35
Liabilities / assets78.1%
Cash & investments$1.53B
Total debt$9.24B
Net cash (debt)-$7.71B
Free cash flow / sales23.5%

Discussion

No comments yet — be the first to weigh in on ZTS.

Sign in to join the discussion.

Scroll to Top